CATALYSIS CAPITAL PARTNERS is pleased to announce that Dr. Hingge Hsu has joined CATALYSIS as a Senior Advisor. Dr. Hsu has contributed to innovation in the life science industry for more than two decades, most recently as a Managing Director in the Private Equity Group at Lehman Brothers in New York, responsible for its healthcare venture effort.
Prior to Lehman, he was a Partner at Schroder Ventures Life Sciences in Boston from 1998 to early 2001. Dr. Hsu also worked at Robertson Stephens in its Healthcare Investment Banking Group. He continues to provide guidance to numerous companies including Fluidigm Corporation, PEAK Surgical, Inc. and Aerovance, Inc. where he is currently a member of the Board. Dr. Hsu graduated from Harvard Business School and Yale Medical School. He trained in internal medicine at Brigham and Women’s Hospital in Boston and received a B.A. degree in Chemistry and Biology at the University of California at San Diego.
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.